IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.452
AS - Asia 5.148
EU - Europa 3.263
SA - Sud America 977
Continente sconosciuto - Info sul continente non disponibili 415
AF - Africa 128
OC - Oceania 13
Totale 17.396
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.207
SG - Singapore 2.789
RU - Federazione Russa 999
IE - Irlanda 719
BR - Brasile 716
IT - Italia 676
CN - Cina 602
HK - Hong Kong 582
VN - Vietnam 441
FR - Francia 260
DE - Germania 168
GB - Regno Unito 112
IN - India 109
CA - Canada 106
KR - Corea 106
BD - Bangladesh 96
AR - Argentina 83
AT - Austria 62
MX - Messico 60
IQ - Iraq 57
TR - Turchia 56
UA - Ucraina 50
CO - Colombia 47
FI - Finlandia 44
JP - Giappone 41
EC - Ecuador 34
ES - Italia 34
VE - Venezuela 34
SA - Arabia Saudita 33
PK - Pakistan 32
ID - Indonesia 31
SE - Svezia 30
ZA - Sudafrica 30
PH - Filippine 28
CL - Cile 24
PL - Polonia 24
NL - Olanda 21
EU - Europa 20
UZ - Uzbekistan 19
MY - Malesia 17
CR - Costa Rica 16
ET - Etiopia 14
JM - Giamaica 14
KE - Kenya 14
JO - Giordania 13
CH - Svizzera 12
EG - Egitto 12
GR - Grecia 12
MA - Marocco 12
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
HN - Honduras 11
UY - Uruguay 11
AU - Australia 10
PS - Palestinian Territory 10
TN - Tunisia 10
DZ - Algeria 9
AZ - Azerbaigian 8
IL - Israele 8
PE - Perù 8
TH - Thailandia 8
BO - Bolivia 7
LT - Lituania 7
NP - Nepal 7
GE - Georgia 6
PA - Panama 6
TT - Trinidad e Tobago 6
CI - Costa d'Avorio 5
KZ - Kazakistan 5
LB - Libano 5
SN - Senegal 5
TW - Taiwan 5
AL - Albania 4
BE - Belgio 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
LY - Libia 4
OM - Oman 4
RS - Serbia 4
CZ - Repubblica Ceca 3
EE - Estonia 3
NI - Nicaragua 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
BB - Barbados 2
BH - Bahrain 2
BZ - Belize 2
CG - Congo 2
IR - Iran 2
LC - Santa Lucia 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
ZW - Zimbabwe 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
Totale 16.971
Salva come PNG Salva come JPEG
Città #
Singapore 2.013
Chandler 944
San Jose 734
Dublin 718
Hong Kong 575
Ashburn 506
Council Bluffs 333
Santa Clara 328
Boardman 286
Dong Ket 273
Altamura 269
San Mateo 233
Lauterbourg 224
Medford 216
Moscow 213
Princeton 213
Lawrence 208
Andover 186
Los Angeles 186
Wilmington 122
New York 113
Seoul 106
Chicago 68
São Paulo 67
Milan 61
Piscataway 58
Arezzo 57
Redwood City 57
Des Moines 52
Ho Chi Minh City 51
Nuremberg 49
Perugia 43
Beijing 42
Dallas 42
Norwalk 42
San Paolo di Civitate 39
Tokyo 39
Hanoi 37
Shanghai 37
Montreal 33
The Dalles 31
Frankfurt am Main 29
Baghdad 25
Helsinki 25
Rio de Janeiro 25
Munich 24
Vienna 24
Brooklyn 23
Buffalo 23
Charlotte 23
Phoenix 23
Redmond 23
Hefei 22
Brasília 21
San Francisco 21
Rome 19
Belo Horizonte 18
London 18
Warsaw 18
Tianjin 17
Atlanta 16
Columbus 16
Kocaeli 16
Mexico City 16
Guayaquil 15
Addis Ababa 14
Dhaka 14
Guangzhou 14
Jacksonville 14
Jeddah 14
Saint Petersburg 14
Santiago 14
Boston 13
Istanbul 13
Johannesburg 13
Porto Alegre 13
Quito 13
Riverbank 13
Secaucus 13
Houston 12
Medellín 12
New Orleans 12
Toronto 12
Curitiba 11
Kingston 11
Kuala Lumpur 11
Nairobi 11
Amman 10
Bogotá 10
Chennai 10
Haiphong 10
Las Vegas 10
Orem 10
San José 10
Shijiazhuang 10
Denver 9
Falkenstein 9
Florence 9
Miami 9
Montevideo 9
Totale 10.810
Salva come PNG Salva come JPEG
Nome #
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 136
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 119
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 116
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 115
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 111
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 110
A prospective study on survival in cancer patients with and without venous thromboembolism. 106
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 106
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 105
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 103
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 101
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 101
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 100
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 99
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 98
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 98
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 97
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 97
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 95
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial 94
Adjuvant therapy in breast cancer and venous thromboembolism 93
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 92
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 89
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 89
Acute endocrine effects of interleukin-12 in cancer patients 88
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 86
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 85
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 85
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 85
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 84
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 83
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 83
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 81
Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma 81
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 80
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 79
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 79
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 79
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 79
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 78
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 78
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 78
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song 77
Targeting BRAF in melanoma: Biological and clinical challenges 77
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 77
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 77
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 77
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 77
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases 77
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 76
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 76
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 75
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 75
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 75
AKT-ions with a TWIST between EMT and MET 75
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 75
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 75
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial 74
Tissue prognostic biomarkers in primary cutaneous melanoma 74
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 74
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 74
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights 74
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 73
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) 73
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 73
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma 72
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 72
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 72
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 72
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 72
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial 72
Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study 71
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 71
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 71
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 70
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 70
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 70
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 70
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer 70
Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study 69
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 69
Is there a right-sided shift for colorectal cancer in women compared with men? 69
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 69
Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival 69
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 69
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience' 69
Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma 69
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 69
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 69
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study 68
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma 68
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 68
Venous thromboembolism and cancer: new issues for an old topic 68
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial 68
Self-monitoring versus standard monitoring of oral anticoagulation 68
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial 68
Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations 68
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities 68
A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy 68
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients 68
Totale 8.104
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.459
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.459
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022944 0 0 0 2 18 7 31 444 9 44 165 224
2022/20233.040 217 524 28 237 274 391 0 164 1.062 9 95 39
2023/2024981 90 154 53 28 18 5 143 9 96 122 99 164
2024/20253.186 34 296 24 82 406 143 92 136 1.173 258 285 257
2025/20266.505 644 444 267 492 841 527 1.223 529 586 652 202 98
2026/20271.805 171 405 563 666 0 0 0 0 0 0 0 0
Totale 17.396